Kristina Hamilton wants to warn others as she continues to fight diffuse systemic scleroderma, with which she was diagnosed ...

AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...

Systemic sclerosis, or scleroderma, causes the hardening of skin and connective tissues. Often, the disease harms other organs, such as the heart, kidneys, lungs, and gastrointestinal tract, and it ...

Add Yahoo as a preferred source to see more of our stories on Google. Tamsin Wright of Marigold Weddings Chris Swanson and Kristina Hamilton Kristina Hamilton, who has Diffuse Systemic Scleroderma, ...

Scleroderma, or systemic sclerosis refers to a disorder in which the skin and connective tissues of the body start to thicken and harden because of the overproduction of a protein called collagen.

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

Systemic sclerosis (SSc), or scleroderma, is a chronic, multisystem autoimmune rheumatic disease characterized by exaggerated fibrosis, vasculopathy, and derangements of the immune system. When ...

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...

CD19-targeting chimeric antigen receptor (CAR) T-cell therapy shows potential to intercept fibrotic organ manifestations and improve disease measures in patients with diffuse cutaneous systemic ...

Systemic sclerosis—or scleroderma that affects the skin and internal organs—is one of the rarest autoimmune diseases, affecting roughly 100,000 people (primarily women) in the United States. However, ...

Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...